AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
Portfolio Pulse from Vandana Singh
AstraZeneca reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with advanced or metastatic non-small cell lung cancer. The drug showed a statistically significant improvement for progression-free survival compared to the current standard of care chemotherapy. However, some adverse events were observed, including some Grade 5 events (Death related to AE), which may be causing investor concern. The drug is jointly developed by AstraZeneca and Daiichi Sankyo.
July 03, 2023 | 9:50 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AstraZeneca's stock is under pressure due to some adverse events observed in the late-stage trial of its lung cancer drug.
The observed adverse events in the trial of AstraZeneca's lung cancer drug could negatively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Daiichi Sankyo, which jointly developed the lung cancer drug with AstraZeneca, may also be affected by the observed adverse events in the trial.
As a joint developer of the lung cancer drug, Daiichi Sankyo's stock could also be negatively impacted by the observed adverse events in the trial.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80